Oxidative-stress: comparison of species specific and tissue specific effects in the marine bivalves Mytilus edulis (L.) and Dosinia lupinus (L.).

This study describes a novel approach to the objective of identifying a suitable biomarker of oxidative-stress in marine animals and evaluates an established assay under controlled experimental conditions in vivo and in vitro. Live animals and tissue homogenates of the euryoxic blue mussel Mytilus edulis (L.), and the stenoxic smooth artemis Dosinia lupinus (L.), were exposed to oxidative-stress generated using a 60Co gamma-radiation source. In live organisms, mortality-rates were significantly different between species. M. edulis showed zero mortality and D. lupinus 30% mortality over 18 h. Protein-carbonyl (PC=O) content was determined by colourimetric assay (total protein-carbonyl) or immunodetection (for individual proteins) in four tissue types: digestive gland, mantle, adductor muscle and foot. In tissue homogenates, digestive gland and adductor muscle of both species showed significant increases (greater for D. lupinus) in PC=O content following irradiation in vitro. All tissues from live animals (with the exception of M. edulis mantle and adductor muscle of D. lupinus which died under irradiation) showed significantly different levels of PC Os following irradiation; D. lupinus PC=O levels were increased whilst in M. edulis PC=O content decreased. In D. lupinus which died during irradiation, PC=O content was greater than in those D. lupinus which survived, particularly in the adductor muscle, the former were inceased by 74% above controls. The findings support the hypothesis that species-specific adaptations to euryoxic and stenoxic environments, and metabolic requirements of different tissues, should result in differing ROS defences.

Liquid chromatographic determination of nalidixic acid in pharmaceutical preparations.

A simple, rapid, and environmentally safe liquid chromatographic (LC) method was developed for the qualitative and quantitative determination of pharmaceutical preparations of nalidixic acid. The new method was applied to commercial preparations of tablets and a suspension of nalidixic acid and found to be satisfactory for both quantitative and qualitative determinations. Previous LC methods either used chloroform to extract, which we were trying to eliminate, or used a mobile phase of about pH 2.5, which will destroy the column coating. The LC system for the new method uses sulfanilic acid as internal standard, a mu-Bondapak C18 column, and a mobile phase of methanol, 0.0045M dibasic potassium phosphate, and 0.0072M hexadecyltrimethylammonium bromide. The detection wavelength is 254 nm. The sample is dissolved in methanol, and an aliquot is injected through a 20 microL injection loop. Average recoveries ranged from 99.4 to 101.3%.

In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.

The effects of WR-2721 [S-2-(3-aminopropylaminoethyl)phosphorothioic acid] in two in vivo and in vitro models of experimental hypercalcemia in the rat were examined. Chronic WR-2721 administration by osmotic minipump (250 mg/kg/24 hr) reduced serum calcium from 12.0 +/- 0.1 to 9.5 +/- 1.0 mg/dl (P less than .01) in rats receiving 1,25-(OH)2 Vitamin D3. Control rats receiving Vitamin D without WR-2721 had a rise in serum calcium to 13.4 +/- 0.2 mg/dl over the same 5-day period. In an experimental form of humoral hypercalcemia of malignancy, the Walker carcinosarcoma tumor-implanted rat, WR-2721 reduced serum calcium from 13.6 +/- 0.3 to 8.4 +/- 0.6 mg/dl by 5 to 6 days (P less than .001). In vitro bone resorption assays utilizing fetal rat long bones in organ culture showed complementary results. WR-2721 (10(-4) M) blocked bone resorption (assayed as percentage of 45Ca release) induced by both conditioned medium derived from cell lines of Walker carcinosarcoma (7.6 +/- 1.4 vs. 24.0 +/- 1.8%, P less than .01) and by addition of 1,25-(OH)2 Vitamin D3 (10(-8) M) (9.8 +/- 0.8 vs. 17.3 +/- 1.0%, P less than .01). These results suggest that WR-2721 may be effective in controlling clinical hypercalcemia due to excess bone resorption.

Liquid chromatographic determination of organic nitrogenous bases in dosage forms: a progress report.

A liquid chromatographic (LC) method has been developed as a general procedure for the assay of the salts of organic nitrogenous bases in a variety of dosage forms. The method uses a nitrile-bonded reverse phase column, a methanol-0.003M ammonium acetate (90 + 10) mobile phase, and photometric detection at 254 nm. The sample is dissolved in the mobile phase and an aliquot is injected through a 20 microL injection loop. Average recovery values for duplicate assays were chlorpheniramine maleate injection 97.8%, chlorpheniramine maleate tablets 99.1%, cyclizine hydrochloride tablets 100.0%, doxylamine succinate tablets 103.3%, mesoridazine besylate tablets 100.4%, pentazocine hydrochloride tablets 103.0%, promethazine hydrochloride injection 98.4%, protriptyline hydrochloride tablets 101.2%, pyrilamine maleate tablets 97.8%, pyrimethamine tablets 100.0%, tripelennamine citrate elixir 100.0%, and tripelennamine hydrochloride tablets 97.2%. Results by this method were in good agreement with those obtained by the USP XX method. This study, which is being continued, will be expanded to include additional drugs.

Rapid high pressure liquid chromatographic determination of amitriptyline hydrochloride in tablets and injectables: collaborative study.

A previously reported high pressure liquid chromatographic method for the determination of amitriptyline hydrochloride in dosage forms was modified to permit its use as a stability-indicating method. The modified method, entailing a nitrile bonded microparticulate column, a methanol-0.005M ammonium acetate (90 + 10) mobile phase, and photometric detection at 239 nm, was collaboratively tested by 10 laboratories. Each collaborator received samples of synthetic and commercial tablets and injections. The recovery from a synthetic injection at the 10.06 mg/mL spiking level averaged 98.6%. The amount of declared found in commercial injections averaged 103.1%. The pooled reproducibility SD (CV%) and repeatability SD (CV%) were +/- 2.12 (2.15) and +/- 1.81 (1.84), respectively. The recovery from synthetic tablet composite at the 7.45% spiking level averaged 102.0%. The amount of declared found for commercial 25 mg and 100 mg tablets averaged 96.7 and 97.9%, respectively. The pooled reproducibility SD (CV%) and repeatability SD (CV%) for these 3 tablet samples were +/- 1.89 (1.86) and +/- 1.66 (1.64), respectively. Content uniformity analysis of commercial 25 mg and 100 mg tablets (n = 10) gave amounts of declared values averaging 100.5% (range 92.4-108.8%) and 99.3% (range 89.6-107.0%), respectively. The pooled reproducibility SD (CV%) and repeatability SD (CV%) were +/- 3.23 (3.2) and +/- 2.78 (2.8), respectively. A commercial injectable preparation spiked with dibenzosuberone was also collaboratively analyzed by a thin layer method. The method was adopted interim official first action.

A serological survey of canine parvovirus infection in New South Wales, Australia.

A serological survey was conducted to ascertain, by haemagglutination inhibition testing, the presence of antibodies to canine parvovirus in 428 dogs in New South Wales, Australia. The first positive canine serum was one collected in May 1978 and the numbers of serologically positive dogs have increased markedly over the last 18 months. Twenty cats which had been vaccinated with feline panleucopenia vaccine were tested for antibody to the canine virus. None of them had a positive titre.